| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 12, 2024 9:00 A.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Buy | TD Cowen | |
| 3/14/2024 | $35.00 | Sector Outperform | Scotiabank |
| 1/18/2024 | $30.00 | Buy | Guggenheim |
| 1/16/2024 | $37.00 | Overweight | Piper Sandler |
| 10/30/2023 | $25.00 | Outperform | RBC Capital Mkts |
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa
Round co-led by Forbion and EQT Life SciencesFinancing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs Successful fundraising demonstrates value of Forbion platform, with multiple Forbion fund strategies supporting VectorY's development since launch AMSTERDAM, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, today announces that its Growth Opportunities Fund has co-led, together with EQT Life Sciences, a €129 million Series A financing in VectorY Therapeutics, a biotech company focusing on the development of innovative vectorized a
TD Cowen initiated coverage of NewAmsterdam Pharma with a rating of Buy
Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00
Guggenheim initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $30.00
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
10-Q - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
20-F/A - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
SC 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the completion of patient enrollment in the pivotal Phase 3 TANDEM clinical trial evaluating the fixed-dose combination ("FDC") of obicetrapib plus ezetimibe in adult patients with Heterozygous Familial Hypercholesterolemia ("HeFH") and/or Atherosclerotic Cardiovascular Disease ("ASCVD") or multiple risk factors for ASCVD, whose LDL-C is not adequately
-- New patent extends patent term for obicetrapib until July 2043 --NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 12,006,305, titled "Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof."
RBC Capital analyst Leonid Timashev reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $31 price target.